Form D · Biotechnology
Contraline, Inc.
Charlottesville, VA · CIK 0001818752
Offering snapshot reported Jun 10, 2026 · SEC filing
- Reported sold
- $55.8M Offering amount: $116M
- Investors reported
- 77 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 29, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 10, 2026 | Initial | $55,804,741 | No comparison | 77 | SEC filing |
| Apr 5, 2022 | Initial | $7,225,669 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-586888
Includes shares of preferred stock issued pursuant to the cancellation of SAFE indebtedness in the amount of $23,429,880.
Source: Form D, filed Jun 10, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gurdane Bhutani | Director |
| Kevin S Eisenfrats | Director, Executive, Promoter |
| Martin J Emerson | Director |
| Michael King | Director |
| Tom Thorpe | Director |
| Iris Van Alderwerelt Van Rosenburgh | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
818 E. Jefferson St Suite 201
Charlottesville, VA, 22902
Charlottesville, VA, 22902